Editorial
Primary endpoints in cancer trials
Abstract
There is an ongoing discussion about the selection of the most appropriate primary endpoint in cancer trials. Most papers are comparing progression-free survival (PFS) with overall survival (OS). Alternatives could be disease-free survival (DFS) or time to treatment failure (TTF). Another option could be the quality of life.
